COX4I2

Across TCGA pan-cancer cohorts, COX4I2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated COX4I2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher COX4I2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COX4I2 expression acts as an unfavorable survival marker.

LSCC, CCRCC, and LUAD are the cancer types where COX4I2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.224	1.000	.004	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.233	1.000	.038	6	view →
LUAD	DFS	Median	All	0.741	1.000	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

COX4I2–LSCC (DFS)

Open the LSCC breakdown →